drugset
drugset / Trial / NCT07161011

Phase 2b Controlled Study of Dosing Techniques - Part B

NCT07161011 ↗

Phase 2 Completed 15 enrolled IVIEW Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Double-masked, dose-response of two concentrations of IVW-1001

Timeline

Start
2025-09-08
Primary completion
2025-11-03
Completion
2025-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject IVW-1001 Unknown 0.2 % —
Subject IVW-1001 Unknown 0.4 % —

Indications

dry eye syndrome